Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.

¹ Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
³ Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
⁴ German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
⁵ Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
⁶ Charles University Hospital, Prague, Czech Republic.
⁷ Royal North Shore Hospital, University of Sydney, Sydney, Australia.
⁸ Kantonsspital Graubünden, Chur, Switzerland.
⁹ Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
¹⁰ Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.
¹¹ Internal Medicine III, University of Ulm, Ulm, Germany.
¹² Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany.
¹³ Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases, University of Cologne, Cologne, Germany; and.
¹⁴ Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.